CITIUS ONCOLOGY INC
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTOR$0.55+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2024 | 2023 | |
|---|---|---|
| Revenues | $— | $— |
| Operating Expenses: | ||
| Research and development | 4,925,001 | 4,240,451 |
| General and administrative | 8,148,929 | 5,915,290 |
| Stock-based compensation – general and administrative | 7,498,817 | 1,965,500 |
| Total Operating Expenses | 20,572,747 | 12,121,241 |
| Loss before Income Taxes | (20,572,747) | (12,121,241) |
| Income tax expense | 576,000 | 576,000 |
| Net Loss | $(21,148,747) | $(12,697,241) |
| Net Loss Per Share – Basic and Diluted | $(0.31) | $(0.19) |
| Weighted Average Common Shares Outstanding – Basic and Diluted | 68,053,607 | 67,500,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.